The World Health Organization (WHO) has released a landmark global guideline on the use of GLP-1 medicines in treating obesity. The guideline emphasizes that while these therapies are highly efficacious, they alone will not reverse the obesity challenge, which requires a multisectoral strategy. The WHO stressed the importance of fair access and called for urgent action on manufacturing, affordability, and health system readiness, noting that without deliberate policy, access could worsen existing health disparities.
